论文部分内容阅读
第三代口服头孢菌素Cefpodoxime pr—oxetil(RU51807)目前处于临床研究中,它是Cefpodoxime(RU51763)的前药(因母药在胃肠道吸收差),吸收后在体内水解
The third generation of oral cephalosporin cefpodoxime pr-oxetil (RU51807) is currently in clinical studies and is a prodrug of cefpodoxime (RU51763) (due to poor absorption of the parent drug in the gastrointestinal tract), which is hydrolyzed in vivo after absorption